PAVmed Inc. (PAVM)
0.76
-0.01 (-1.04%)
At close: Mar 28, 2025, 3:59 PM
0.72
-4.82%
After-hours: Mar 28, 2025, 05:27 PM EDT
-1.04% (1D)
| Bid | 0.7 |
| Market Cap | 12.7M |
| Revenue (ttm) | 5.31M |
| Net Income (ttm) | 70.56M |
| EPS (ttm) | 0.5 |
| PE Ratio (ttm) | 1.51 |
| Forward PE | -0.42 |
| Analyst | Buy |
| Ask | 0.8 |
| Volume | 104,568 |
| Avg. Volume (20D) | 196,761 |
| Open | 0.76 |
| Previous Close | 0.77 |
| Day's Range | 0.71 - 0.77 |
| 52-Week Range | 0.57 - 2.43 |
| Beta | 1.19 |
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 27, 2016
Employees 39
Stock Exchange NASDAQ
Ticker Symbol PAVM
Website https://www.pavmed.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PAVM stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 2410.57% from the latest price.
Stock ForecastsNext Earnings Release
PAVmed Inc. is scheduled to release its earnings on May 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+7.31%
PAVmed shares are trading higher on possible conti...
Unlock content with
Pro Subscription
10 months ago
+15.63%
PAVmed shares are trading higher after the company reported better-than-expected Q1 Adj. EPS results.
